A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Trial Profile

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Lifastuzumab vedotin (Primary) ; Bevacizumab; Carboplatin
  • Indications Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 13 Sep 2016 Patients with non-squamous non-small cell lung cancer are also included in the study. Treatment arms changed from 3 to 4.
    • 13 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top